admin

In the Phase 3 of the clinical trials conducted by GW Pharmaceuticals and the Ohio State University on the effectiveness of Epidiolex, results showed that the cannabis-based drug lowered the number of epileptic seizures experienced by children with Lennox-Gastaut syndrome by half. What Is Lennox-Gastaut Syndrome? The Lennox-Gastaut syndrome is one of the rare forms […]

by

Maxim Group initiated coverage on shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) in a research note published on Thursday morning. The firm issued a buy rating and a $135.00 price objective on the biopharmaceutical company’s stock. “Epilepsy remains a challenging indication to treat, with over a third of patients (750k patients in the U.S.) who are […]

by

In the Phase 3 of the clinical trials conducted by GW Pharmaceuticals and the Ohio State University on the effectiveness of Epidiolex, results showed that the cannabis-based drug lowered the number of epileptic seizures experienced by children with Lennox-Gastaut syndrome by half. What Is Lennox-Gastaut Syndrome? The Lennox-Gastaut syndrome is one of the rare forms […]

by

Home » Brain Function » Cannabidiol seen to provide overall improvement for severe epilepsy patients By: Dr. Victor Marchione | Brain Function | Friday, April 21, 2017 – 05:00 AM Seizures are often dramatized on television and in movies—they depict a person collapsing to the ground while they convulse (shake), contracting every muscle in their […]

by

Cannabinoids accomplish what Western medicine can’t – again! While approximately 138,000 American kids suffer from Tourette syndrome (TS) – roughly 1 in every 162 adolescents under the age of 17 – a single case study on treatment resistant Tourette syndrome indicates that cannabinoids may provide a therapeutic option; offering a hopeful light at the end […]

by

Maxim Group Issues a Buy Rating on GW Pharma By Ryan Adsit Maxim Group analyst Lauren Chung reiterated a Buy rating on GW Pharma (NASDAQ: GWPH) today and set a price target of $135. The company’s shares opened today at $115.82. Chung said: “Epilepsy remains a challenging indication to treat, with over a third of […]

by

Instead of gambling on which marijuana stock will move the most, many investors choose to focus on Medical Marijuana Companies, especially those focusing their research on cannabinoids (CBD), which are the active chemical components of the cannabis plant. Opposed to tetrahydrocannabinol (THC), which creates the pleasant psychoactive “high” that cannabis users are familiar with, CBD […]

by

Many parents come to my office seeking help for their children suffering with autism.   The three main symptoms that are challenging for these families are communication difficulties, repetitive behaviors, and social challenges, including tantrums and self-injurious behavior.  Although the FDA has approved two medications, both antipsychotics, for treating the irritability associated with autism, they have […]

by